# CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)

> **NCT02043665** · PHASE1 · COMPLETED · sponsor: **Viralytics** · enrollment: 85 (actual)

## Conditions studied

- Non-small Cell Lung Cancer
- Bladder Cancer

## Interventions

- **BIOLOGICAL:** CVA21/pembrolizumab

## Key facts

- **NCT ID:** NCT02043665
- **Lead sponsor:** Viralytics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12-18
- **Primary completion:** 2020-01-10
- **Final completion:** 2020-01-10
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2023-05-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02043665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02043665, "CVA21 and Pembrolizumab in NSCLC & Bladder Cancer (VLA-009 STORM/ KEYNOTE-200)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02043665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*